Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientctpatients mustenrollmentgreater than
  Phrases that lowered it: nasalpastinhaledtestadministered
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.7% (raises risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 96.2% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 38 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: single (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 50 (raises risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Allocation: non randomized (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nitric Oxide to Treat Pulmonary Embolism NCT01939301 · started 2013 · scored riskier than 90% of active trials completed
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH NCT02725372 · started 2016 · scored riskier than 97% of active trials terminated
• 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF NCT02267655 · started 2015 · scored riskier than 50% of active trials completed
• Inhaled Nitrite in Subjects With Pulmonary Hypertension NCT01431313 · started 2012 · scored riskier than 63% of active trials completed
• A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) NCT01725256 · started 2012 · scored riskier than 82% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.